<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(1)</volume><submitter>Liu T</submitter><pubmed_abstract>Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b) is a newly identified molecule associated with neuromodulation. However, the role of Lypd6b in regulating the tumor microenvironment and its impact on CD8&lt;sup>+&lt;/sup> T cell-mediated antitumor immunity remain unknown. Here, we observe that Lypd6b expression is increased significantly in colorectal cancer (CRC) tumor tissues compared to normal tissues. Lypd6b is mainly expressed in CD8&lt;sup>+&lt;/sup> T cells in tumor tissues. Lypd6b knockout (Lypd6b&lt;sup>-/-&lt;/sup>) mice are resistant to AOM/DSS-induced tumorigenesis. Furthermore, global deficiency or CD8&lt;sup>+&lt;/sup> cell deficiency of Lypd6b inhibits MC38 or CMT-93 tumor growth and promotes the infiltration of CD8&lt;sup>+&lt;/sup> T cells. Mechanistical</pubmed_abstract><journal>Nature communications</journal><pagination>675</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12820146</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Lypd6b depletion promotes CD8&amp;lt;sup&amp;gt;+&amp;lt;/sup&amp;gt; T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer.</pubmed_title><pmcid>PMC12820146</pmcid><pubmed_authors>Yao J</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Xu D</pubmed_authors><pubmed_authors>Liu Q</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Liu T</pubmed_authors><pubmed_authors>Yan X</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Cheng L</pubmed_authors><pubmed_authors>Zeng F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lypd6b depletion promotes CD8&amp;lt;sup&amp;gt;+&amp;lt;/sup&amp;gt; T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer.</name><description>Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b) is a newly identified molecule associated with neuromodulation. However, the role of Lypd6b in regulating the tumor microenvironment and its impact on CD8&lt;sup>+&lt;/sup> T cell-mediated antitumor immunity remain unknown. Here, we observe that Lypd6b expression is increased significantly in colorectal cancer (CRC) tumor tissues compared to normal tissues. Lypd6b is mainly expressed in CD8&lt;sup>+&lt;/sup> T cells in tumor tissues. Lypd6b knockout (Lypd6b&lt;sup>-/-&lt;/sup>) mice are resistant to AOM/DSS-induced tumorigenesis. Furthermore, global deficiency or CD8&lt;sup>+&lt;/sup> cell deficiency of Lypd6b inhibits MC38 or CMT-93 tumor growth and promotes the infiltration of CD8&lt;sup>+&lt;/sup> T cells. Mechanistical</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-14T05:04:55.397Z</modification><creation>2026-06-14T03:08:42.245Z</creation></dates><accession>S-EPMC12820146</accession><cross_references><pubmed>41381524</pubmed><doi>10.1038/s41467-025-67344-w</doi></cross_references></HashMap>